We include products we think are useful. If you buy through the links on this page, we may receive a commission.
- Is there a Zepbound coupon in the United States? - May 3, 2026
- Does a dental irrigator help with gingivitis? - May 2, 2026
- How much does Jardiance cost in Spain? - May 1, 2026
Yes. In the United States, Qsymia already has a generic, and the FDA approved the first generic version of phentermine and topiramate extended-release capsules on June 25, 2024. A further therapeutically equivalent approval followed in 2025.
What exactly is the generic version of Qsymia?
According to the FDA, Qsymia is a prescription drug containing phentermine and extended-release topiramate.
The official label adds that it is used in conjunction with a reduced-calorie diet and increased physical activity for chronic weight management in certain adults and in patients aged 12 years and over with obesity.
The NIDDK also includes Qsymia among the drugs approved by the FDA in the United States for long-term weight management.
What has the FDA approved regarding the generic version of Qsymia?
The FDA added these capsules to its list of first-time generic approvals in 2024 and also approved another abbreviated application in 2025 for a bioequivalent and therapeutically equivalent version to Qsymia.
The 2025 letter expressly states that this version is bioequivalent and therapeutically equivalent to the reference medicine Qsymia ER from Vivus.
In that documentation, Qsymia continues to appear as the reference drug on which generic approvals are based.
What's the difference between the brand name and the generic version of Qsymia?
Teva's product information lists its phentermine and topiramate extended-release capsules as an equivalent to the brand name Qsymia and rated AB.
That same data sheet shows four concentrations and 30-capsule packs, in line with the four concentrations included in the official approvals and product data sheets.
DailyMed maintains a tab for Qsymia and another for generic phentermine and topiramate extended-release capsules.
Why is it important to look at the full name?
In 2024, the FDA approved a modification to Qsymia's REMS program to add an authorized generic.
Another 2025 approval letter further confirms an approved REMS for a generic version of phentermine and extended-release topiramate.
The official REMS website indicates that the program is aimed at certified pharmacies and patients with reproductive capacity.
Therefore, in the United States the product may appear in the documentation as Qsymia or as phentermine and topiramate extended-release capsules.
This content is for informational purposes only and is not a substitute for medical advice. Before starting or changing any treatment, consult a healthcare professional.
